Clinical Evidence

The GlycoMark test has been studied in various groups including individuals with type 1, type 2 and gestational diabetes and people with kidney disease.

  • Over 1,300 studies and abstracts in the scientific and medical journals describe the GlycoMark test (1,5-Anhydroglucitol, aka 1,5-AG) as a specific indicator of recent hyperglycemic excursions.1  
  • More than 500 of these studies support the use of the GlycoMark test for its use in glycemic control.
  • More than 40 clinical trials conducted at hospitals and universities around the world have evaluated the GlycoMark test in comparison to other measures of glucose control, including continuous glucose monitoring, oral glucose tolerance tests, A1C and fructosamine/glycated albumin.

The GlycoMark Compendium of Evidence provides a summary of all data relevant to 1,5-AG.



  • The GlycoMark test is not affected by hemoglobinopathies, such as anemias, sickle cell disease or malaria,  because it is not a hemoglobin glycosylation marker like A1c.
  • The GlycoMark test has been tested and found to be unaffected by hemoglobin (125 mg/dL), triglycerides (1153 mg/dL), bilirubin (40 mg/dL), glucose (1000 mg/dL),  maltose (500 mg/dL), ascorbic acid (25 mg/dL), uric acid (20 mg/dL), urea (20 mg/dL) and creatinine (10 mg/dL).



1Data on file, see package insert for details.